Results 31 to 40 of about 15,210 (229)

Clinical Results of Hypomethylating Agents in AML Treatment [PDF]

Journal of Clinical Medicine, 2014
Epigenetic changes play an important role in the development of acute myeloid leukemia (AML). Unlike gene mutations, epigenetic changes are potentially reversible, which makes them attractive for therapeutic intervention. Agents that affect epigenetics are the DNA methyltransferase inhibitors, azacitidine and decitabine.
Cruijsen, Marjan, Lübbert, Michael, Wijermans, Pierre W., Huls, Gerwin   +3 more
openaire   +3 more sources

Natural killer cell response to chemotherapy-stressed cancer cells: Role in tumor immunosurveillance. [PDF]

, 2017
Natural killer (NK) cells are innate cytotoxic lymphoid cells that actively prevent neoplastic development, growth, and metastatic dissemination in a process called cancer immunosurveillance.
Borrelli, Cristiana, Cippitelli, Marco, Fionda, Cinzia, Santoni, Angela, Soriani, Alessandra, Zingoni, Alessandra   +5 more
core   +1 more source

Angioimmunoblastic T‐cell lymphoma after acute myeloid leukemia: Alleged common pathogenesis. A case report and literature review

Clinical Case Reports, 2020
The genomic landscape of AITL is characterized by mutation of epigenetic modifiers. This gene expression pattern resembles myeloid diseases and shows a potential role for hypomethylating agents as possible therapy for AITL.
Isabel Iturrate, Javier Loscertales, Elena Fernández‐Ruiz, Patricia Muñoz, Consuelo López, Luciana del Campo, Cecilia Muñoz, Adrián Alegre   +7 more
doaj   +1 more source

Myelodysplastic syndromes: Where do we stand?

Asian Journal of Oncology, 2016
Myelodysplastic syndromes (MDS) are fairly common hematological disorder of elderly. They are a group of clonal malignant hematopoietic stem cell disorders characterized by dysplastic morphology, variable cytopenia and a variable threat of transformation
Nitin Sood, Bhuvan Chugh, Esha Singhal, Ritesh Sachdev, Shalini Goel, Gajendra Smeeta   +5 more
doaj   +1 more source

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting

Experimental Hematology & Oncology, 2023
Venetoclax (VEN), the first selective Bcl-2 inhibitor, has shown efficacy and safety both as monotherapy and in combination with other agents in the treatment of newly diagnosed acute myeloid leukemia (AML), while its role in relapsed or refractory (R/R)
Xubo Gong, Yi Zhang, Xin He, Milad Moloudizargari, Teng Yu, Lin Wang, Weiwei Liu, Lan Jin, Huiying Xu, Yang Xu, Zhihua Tao, Wenbin Qian   +11 more
doaj   +1 more source

RRx-001, A novel dinitroazetidine radiosensitizer. [PDF]

, 2016
The 'holy grail' in radiation oncology is to improve the outcome of radiation therapy (RT) with a radiosensitizer-a systemic chemical/biochemical agent that additively or synergistically sensitizes tumor cells to radiation in the absence of significant ...
Bednarski, Mark, Cabrales, Pedro, Knox, Susan, Ning, Shoucheng, Oronsky, Arnold, Oronsky, Bryan, Peehl, Donna, Scicinski, Jan   +7 more
core   +1 more source

Epigenetic targeting of ovarian cancer stem cells [PDF]

, 2014
Emerging results indicate that cancer stem-like cells contribute to chemoresistance and poor clinical outcomes in many cancers, including ovarian cancer.
Cardenas, Horacio, Condello, Salvatore, Fang, Fang, Liu, Yunlong, Matei, Daniela, Nephew, Kenneth P., Segar, Matthew, Taverna, Pietro, Wang, Yinu   +8 more
core   +2 more sources

Non-catalytic Roles of Tet2 Are Essential to Regulate Hematopoietic Stem and Progenitor Cell Homeostasis [PDF]

, 2019
The Ten-eleven translocation (TET) enzymes regulate gene expression by promoting DNA demethylation and partnering with chromatin modifiers. TET2, a member of this family, is frequently mutated in hematological disorders.
Abdel-Wahab, Agathocleous, Anders, Asmar, Chen, Cimmino, Cimmino, Delhommeau, Deplus, Dominguez, Fabiani, Garcia-Manero, Gardin, Giagounidis, Goasguen, Issa, Ito, Ito, Ito, Ito, Jiao, Kim, Ko, Komrokji, Kosmider, Lemonnier, Li, Love, Moran-Crusio, Mouly, Pan, Purton, Quivoron, Reddy, Sato, Schneider, Song, Tahiliani, Tefferi, Trapnell, Wang, Wang, Williams, Wu, Yu, Zhang   +45 more
core   +1 more source

Hypomethylating agent versus venetoclax combination: an electronic health records-based target trial emulation among Asian elderly patients with newly diagnosed acute myeloid leukaemia in Hong Kong

Therapeutic Advances in Hematology
Background: The pivotal trial on venetoclax and hypomethylating agents in unfit elderly acute myeloid leukaemia (AML) has got FDA approval. However, Asian patients were under-represented and showed no survival advantage.
Qiwen Fang, Chi Yeung Fung, Jiaqi Wang, Wing Hei Lai, Raymond S. M. Wong, Bonnie C. S. Kho, June S. M. Lau, Vivien W. M. Mak, Chung Yin Ha, Xue Li, Anskar Yu-Hung Leung   +10 more
doaj   +1 more source

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization. [PDF]

, 2016
RRx-001, an experimental systemically non-toxic epi-immunotherapeutic agent, which potentiates the resensitization of resistant cancer cells to formerly effective therapies, is under active investigation in several clinical trials that are based on ...
Brzezniak, Christina, Cabrales, Pedro, Caroen, Scott Z, Carter, Corey A, Degesys, Aiste, Jenkins, John, Oronsky, Bryan T, Reid, Tony, Scicinski, Jan J   +8 more
core   +3 more sources